Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

INTRODUCTION: Our patient treated with pembrolizumab and axitinib is one of the longest survivors in Japan on KEYNOTE 426, despite adverse events, including delayed‐onset hepatitis. We herein present a detailed clinical course and short discussion on the case. CASE PRESENTATION: This was a 49‐year‐o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimoto, Koshiro, Shirotake, Suguru, Miyama, Yu, Kaneko, Go, Kanao, Kent, Igarashi, Daisuke, Takahashi, Takayuki, Umezawa, Yuta, Yasuda, Masanori, Oyama, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057749/
https://www.ncbi.nlm.nih.gov/pubmed/35509782
http://dx.doi.org/10.1002/iju5.12422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057749/
https://www.ncbi.nlm.nih.gov/pubmed/35509782
http://dx.doi.org/10.1002/iju5.12422

Ejemplares similares